CD46 and urinary bladder cancer: In summary, our data indicate that use of Ad5/35 fiber chimeric gene therapy vectors re-directed to CD46 provides an effective approach to enhance viral gene transduction efficacy in CAR-deficient cancers, including a subset of bladder cancers.